StreetInsider.com News Articles

RAMM Pharma Corp. Provides Additional Disclosure in Connection with its Upcoming Special Meeting of Shareholders

Fri, 07 Nov 2025 10:11:00 -0500

TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or “RAMM”) (CSE: RAMM) wishes to supplement the information contained in its management information circular (the “Circular”) dated October 9, 2025 regarding its proposed transaction (the "Transaction”) with The Global South S.A.S (“Global South”) following a review by the Ontario Securities Commission, which Transaction will be subject to the approval of the minority shareholders at the Company’s upcoming Special Meeting of Shareholders (the “Meeting”) scheduled to take place on November 12, 2025 at 2:30 p.m. (Toronto Time). In light of

RAMM Pharma Corp. Provides Additional Disclosure in Connection with its Upcoming Special Meeting of Shareholders

Fri, 07 Nov 2025 10:11:00 -0500

RAMM Pharma Corp. Provides Additional Disclosure in Connection with its Upcoming Special Meeting of Shareholders

Fri, 07 Nov 2025 10:11:00 -0500

RAMM Pharma Corp. Provides Additional Disclosure in Connection with its Upcoming Special Meeting of Shareholders

Fri, 07 Nov 2025 10:11:00 -0500

RAMM Pharma Corp. Provides Additional Disclosure in Connection with its Upcoming Special Meeting of Shareholders

Fri, 07 Nov 2025 10:11:00 -0500

RAMM Pharma Corp. Provides Additional Disclosure in Connection with its Upcoming Special Meeting of Shareholders

Fri, 07 Nov 2025 10:11:00 -0500

RAMM Pharma Corp. Provides Additional Disclosure in Connection with its Upcoming Special Meeting of Shareholders

Fri, 07 Nov 2025 10:11:00 -0500

RAMM Pharma Corp. Provides Additional Disclosure in Connection with its Upcoming Special Meeting of Shareholders

Fri, 07 Nov 2025 10:11:00 -0500

RAMM Pharma Corp. Provides Additional Disclosure in Connection with its Upcoming Special Meeting of Shareholders

Fri, 07 Nov 2025 10:11:00 -0500

RAMM Pharma Corp. Provides Additional Disclosure in Connection with its Upcoming Special Meeting of Shareholders

Fri, 07 Nov 2025 10:11:00 -0500

Early Warning Press Release Respecting the Acquisition of Common Shares of RAMM PHARMA Corp.

Fri, 30 May 2025 19:35:00 -0500

TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- Jack Burnett ("CEO") today announced that he has filed an early warning report (the "Early Warning Report") under National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues in connection with the acquisition of securities of RAMM PHARMA Corp (CSE: RAMM) (the “Company”). Pursuant to the terms of a Stock Transfer Agreement (the “Agreement”) dated May 30, 2025, between Jack Burnett, as purchaser, and Armando Blankleider, as vendor (“Vendor”), CEO acquired 4.667.000 common shares of the Company (the “Common Shares”) for consideration of CDN

Early Warning Press Release Respecting the Acquisition of Common Shares of RAMM PHARMA Corp.

Fri, 30 May 2025 19:35:00 -0500

Early Warning Press Release Respecting the Acquisition of Common Shares of RAMM PHARMA Corp.

Fri, 30 May 2025 19:35:00 -0500

Early Warning Press Release Respecting the Acquisition of Common Shares of RAMM PHARMA Corp.

Fri, 30 May 2025 19:35:00 -0500

Early Warning Press Release Respecting the Acquisition of Common Shares of RAMM PHARMA Corp.

Fri, 30 May 2025 19:35:00 -0500

Early Warning Press Release Respecting the Acquisition of Common Shares of RAMM PHARMA Corp.

Fri, 30 May 2025 19:35:00 -0500

Early Warning Press Release Respecting the Acquisition of Common Shares of RAMM PHARMA Corp.

Fri, 30 May 2025 19:35:00 -0500

Early Warning Press Release Respecting the Acquisition of Common Shares of RAMM PHARMA Corp.

Fri, 30 May 2025 19:35:00 -0500

RAMM Pharma Corp. Provides Update on Canapar

Tue, 21 Jan 2025 17:00:00 -0500

Not for Dissemination in the US or through US Newswire Services

TORONTO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), is exploring strategic options for the potential sale of its subsidiary, Canapar Corp., and/or its industrial facility located in Ragusa, Italy.

This decision is part of RAMM's ongoing efforts to streamline operations and focus on its operating businesses while seeking potential growth opportunities. The potential sale is aimed at enhancing shareholder value and ensuring the long-term sustainability

RAMM Pharma Corp. Provides Update on Canapar

Tue, 21 Jan 2025 17:00:00 -0500

Not for Dissemination in the US or through US Newswire Services

RAMM Pharma Corp. Provides Update on Canapar

Tue, 21 Jan 2025 17:00:00 -0500

Not for Dissemination in the US or through US Newswire Services

RAMM Pharma Corp. Provides Update on Canapar

Tue, 21 Jan 2025 17:00:00 -0500

Not for Dissemination in the US or through US Newswire Services

RAMM Pharma Corp. Provides Update on Canapar

Tue, 21 Jan 2025 17:00:00 -0500

Not for Dissemination in the US or through US Newswire Services

RAMM Pharma Corp. Provides Update on Canapar

Tue, 21 Jan 2025 17:00:00 -0500

Not for Dissemination in the US or through US Newswire Services

RAMM Pharma Corp. Provides Update on Litigation

Wed, 11 Dec 2024 10:46:00 -0500

Not for Dissemination in the US or through US Newswire Services

TORONTO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), is providing an update on its dispute with Sergio Martines and Naturale Science Inc. (plaintiffs), as previously reported in its press release of May 21st 2024.

The Judge has dismissed the plaintiffs’ claim in the amount of CAD 3,139,931.30 and has awarded Martines CAD 14,971.80 in unpaid expenses. The Judge has also dismissed RAMM’s counterclaim in the amount of CAD 14,220,000.